Introduction
============

Alzheimer's disease (AD) affects 5%--15% of the population over 65 years, and about 20% of individuals over 80 years. AD is characterized by a gradual onset of multiple cognitive deficits and is associated with continuing cognitive decline. There is a high prevalence of psychotic symptoms ([@b46-cia-3-491]) and behavioral disturbances in AD ([@b19-cia-3-491]; [@b21-cia-3-491]). A review of studies that assessed the prevalence of psychosis associated with AD showed a median prevalence rate of 41.1% (range, 12.2%--74.1%) ([@b48-cia-3-491]); however, the patients followed up in the outpatient clinics showed lower rates ([@b4-cia-3-491]). Psychotic symptoms have been linked to increased cognitive and functional decline ([@b9-cia-3-491]; [@b36-cia-3-491]) leading to caregiver distress ([@b22-cia-3-491]; [@b28-cia-3-491]) and an increased likelihood of institutionalization ([@b36-cia-3-491]) in patients with AD. [@b30-cia-3-491] have defined the diagnostic criteria for psychosis of AD ([Table 1](#t1-cia-3-491){ref-type="table"}).

Among the psychotropic medications, antipsychotics are the most studied treatment for psychosis, aggression, and agitation in elderly patients with dementia ([@b20-cia-3-491]; [@b33-cia-3-491]). These studies have shown the efficacy of atypical antipsychotics in treating some of the behavioral symptoms that are associated with AD ([@b32-cia-3-491]; [@b53-cia-3-491]; [@b55-cia-3-491]; [@b6-cia-3-491]; [@b15-cia-3-491], [@b14-cia-3-491]; [@b63-cia-3-491]). Even though there is no psychotropic medication that is approved by the US Food and Drug Administration (FDA) for the treatment of psychosis of AD, a number of expert consensus statements recommend the use of atypical antipsychotic agents as a first-line pharmacologic approach to treatment ([@b3-cia-3-491]; AGS/AAGP). Despite these findings, only a few studies have prospectively evaluated the antipsychotic effects of this class of compounds in patients with AD using the criteria defined by [@b30-cia-3-491]. In contrast, most published studies with atypical agents have also included patients with vascular and mixed dementias, and those with behavioral disturbances, such as agitation.

Safety and tolerability of a medication is of great concern while treating the elderly due to their increased sensitivity to adverse events (AEs), the increased likelihood of co-morbid health problems (eg, cardiovascular disease), and the potential for some side effects to worsen the progression of dementia ([@b33-cia-3-491]). Studies have shown that risperidone, olanzapine, and quetiapine can reduce psychotic symptoms and behavioral disturbances in patients with dementia ([@b32-cia-3-491]; [@b17-cia-3-491]; [@b53-cia-3-491]; [@b39-cia-3-491]; [@b55-cia-3-491]; [@b6-cia-3-491]; [@b15-cia-3-491], [@b14-cia-3-491]; [@b63-cia-3-491]. However, the side-effect profiles of individual atypical antipsychotics, especially the metabolic effects may adversely influence their overall effectiveness and acceptability ([@b29-cia-3-491]; [@b41-cia-3-491]). Movement disorders, sedation, and orthostasis are associated with an increased risk of falls and subsequent fractures. Anticholinergic side effects may lead to delirium in the elderly and require additional treatment. Analyses of safety data from several studies have raised concerns about an increased risk of cerebrovascular adverse events (CVAEs), such as stroke, with the use of some atypical antipsychotics compared with placebo in elderly patients with dementia ([@b61-cia-3-491], [@b62-cia-3-491]). This has led FDA to issue warnings on the use of atypical antipsychotics in the treatment of behavioral and psychological symptoms in elderly patients with dementia, particularly those with a history of cerebrovascular disease ([@b56-cia-3-491]; Health Canada; MHRA). More recently, the FDA issued a separate warning regarding an increased mortality risk in elderly patients with dementia who were treated with atypical antipsychotics ([@b57-cia-3-491]). We have dealt with these issues in detail in our recent review article ([@b37-cia-3-491]).

Aripiprazole is a novel atypical antipsychotic that has shown rapid and sustained efficacy and tolerability in short-term and long-term controlled clinical trials and retrospective studies in patients with schizophrenia, schizoaffective disorder and bipolar disorder (Liebermann 2004; [@b38-cia-3-491]; [@b49-cia-3-491]). Recently FDA approved the use of aripiprazole as an adjunctive to antidepressants for the treatment of major depressive disorder in adults ([@b47-cia-3-491]). Aripiprazole is a partial D~2~-receptor agonist ([@b7-cia-3-491]), 5-HT~2A~ receptor antagonist ([@b8-cia-3-491]), and a partial agonist at 5-HT~1A~ receptors ([@b31-cia-3-491]). In addition, aripiprazole has been shown to exhibit moderate affinity for the alpha~1~, alpha~2~ and histamine H~1~ receptors and negligible affinity for muscarinic M~1~ receptors ([@b18-cia-3-491]; [@b47-cia-3-491]).

Three 10-week, placebo-controlled, randomized, double-blind clinical studies have evaluated the efficacy and tolerability of aripiprazole for the treatment of psychosis related to AD ([Table 2a](#t2a-cia-3-491){ref-type="table"}) ([@b54-cia-3-491]; [@b16-cia-3-491]; [@b44-cia-3-491]). Of these, the studies conducted by De Deyn et al and Streim et al examined flexible dosing of aripiprazole (2--15 mg/d), and Mintzer et al studied fixed doses of aripiprazole (2 mg/d, 5 mg/d, 10 mg/d). Patients in the Streim et al and Mintzer et al studies were either full time nursing home or assisted living facility residents, while patients in the De Deyn et al study were living in assisted living facilities or adult communities, or with a caregiver. The inclusion criteria were delusions/hallucinations lasting for 1 month or longer, Mini Mental State Exam (MMSE; Fostein et al 1975) score of 6--24, and score of more than 6 on delusions or hallucinations items of Neuropsychiatric Inventory (NPI; [@b13-cia-3-491]) scale at baseline.

In the [@b16-cia-3-491] study, 208 outpatients (mean age 81.5 years, range 55--95) with AD-associated psychosis and mean MMSE score of 14.35 (aripiprazole) and 14.13 (placebo), were randomized to aripiprazole (n = 106) or placebo (n = 102). The initial aripiprazole dose of 2 mg/d was titrated upwards (5, 10, or 15 mg/d) usually every 2 weeks according to efficacy and tolerability. Overall, 172 patients (83%) completed the study. Mean aripiprazole dose at end point was 10.0 mg/d. Patients in this study were noninstitutionalized, in contrast to most studies with other atypicals published to date, which included institutionalized patients ([@b32-cia-3-491]; [@b53-cia-3-491]; [@b55-cia-3-491]; [@b6-cia-3-491]; [@b15-cia-3-491], [@b14-cia-3-491]; [@b63-cia-3-491]). In this study, the degree of cognitive impairment (mean MMSE, 14.35 for aripiprazole, 14.13 for placebo) was less compared with most of the studies with other atypicals (mean MMSE, 6.1--9.3).

In the [@b54-cia-3-491] study, 256 inpatients (mean age 83 years, range 59--96) with AD-associated psychosis and mean MMSE score of 12.9 were randomized to aripiprazole (n = 131) or placebo (n = 125). The suggested titration for this study was: week 1: 2 mg/d; week 2--3: 5mg/d; week 4--5: 10 mg/d; week 6--10: 15 mg/d. Mean aripiprazole dose at end point was 8.6 mg/d.

In the [@b44-cia-3-491] study, 487 inpatients (mean age 82.5 years, range 56--97) with AD-associated psychosis and mean MMSE score of 12.4 were randomized to fixed doses of aripiprazole, 2 mg/d (n = 118), 5 mg/d (n = 122), 10 mg/d (n = 126) (patients were started on 5 mg/d for 7 days and the dose was then increased to 10 mg/d), or placebo (n= 121). By week 6, patients with Clinical Global Impression of Improvement (CGI-I; [@b25-cia-3-491]) score of ≥4 were allowed open-label treatment with aripiprazole through week 10. In total, 284 patients completed 10 weeks of double-blind therapy.

Results
=======

Efficacy ([Table 2b](#t2b-cia-3-491){ref-type="table"})
-------------------------------------------------------

### Primary outcome measures

In the [@b16-cia-3-491] study, the caregiver-assessed NPI Psychosis subscale ([@b13-cia-3-491]) score showed improvements in both groups (aripiprazole −6.55, placebo −5.52; p = 0.17 at end point), but the difference between aripiprazole and placebo was not statistically significant.

In the [@b54-cia-3-491] study, there was no statistically significant difference between aripiprazole and placebo on the NPI Psychosis subscale score at week 10. There were decreases in Clinical Global Impression-Severity of Illness (CGI-S; [@b25-cia-3-491]) scores in both aripiprazole and placebo groups, but the difference in the mean change in CGI-S in aripiprazole vs placebo was significant (p \< 0.05) only at week 8.

In the [@b44-cia-3-491] study, there was a statistically significant difference between aripiprazole and placebo (aripiprazole 10 mg/d, −6.87. placebo, −5.13. p 0.013) on the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis subscale ([@b25-cia-3-491]; [@b13-cia-3-491]; [@b60-cia-3-491]) score at week 10. Mean change in NPI-NH Psychosis subscale score was also significant for the aripiprazole 5 mg group vs placebo at week 8 (p \< 0.05). There was a statistically significant difference (p \< 0.05) in the response to treatment as defined by ≥50% reduction in the NPI-NH Psychosis subscale score at week 10 for aripiprazole (65%) vs placebo (50%).

### Secondary outcome measures

In the [@b16-cia-3-491] study, aripiprazole-treated patients showed significantly greater improvements from baseline in physician assessed Brief Psychiatric Rating Scale (BPRS) ([@b45-cia-3-491]) Psychosis and BPRS Core subscale scores at end point compared with placebo. There were no statistically significant differences between aripiprazole and placebo in the mean change in BPRS total score (aripiprazole −8.53, placebo −6.58; p value not significant), NPI total (aripiprazole −9.75, placebo −11.20; p value not significant), CGI-S (aripiprazole −0.69, placebo −0.54; p value not significant ), CGI-I (aripiprazole 3.17, placebo, 3.07; p value not significant). Patients in both the aripiprazole and placebo groups showed little change in cognitive function over the course of the study, with minimal mean changes (\< 1 point) in MMSE score observed from baseline to end point (aripiprazole −0.81, placebo −0.53; p 0.001). The investigators explained the small improvement in MMSE scores seen in the placebo group as a possible response to the increased attention patients received during the study. The minimal changes observed in both groups and high mean baseline scores, coupled with the wide variation in baseline MMSE scores (from 2 to 23), suggested that these are of little clinical significance. Aripiprazole has negligible affinity for muscarinic M~1~ receptors, and hence has a low potential for cognitive impairment, and has shown improvements in cognitive function in a study in patients with schizophrenia or schizoaffective disorder ([@b12-cia-3-491]).

In the [@b54-cia-3-491] study, there was a statistically significant difference (p = 0.006) in the response to treatment as defined by ≥50% reduction in the NPI total score at week 10 for aripiprazole (46%) and placebo (28%). There were statistically significant improvements in the NPI-NH total scores (aripiprazole −16.4, placebo −10.0; p 0.009), BPRS total score (aripiprazole, −7.7 placebo, −5.1; p 0.031) and Cornell Depression in Dementia Scale (CDDS; [@b2-cia-3-491]) total score (aripiprazole −0.13, placebo −1.98; p 0.006) at week 10. There were statistically significant (p \< 0.05) improvements with aripiprazole vs placebo group in Cohen-Mansfield Agitation Inventory (CMAI; [@b11-cia-3-491]; [@b10-cia-3-491]; [@b43-cia-3-491]; [@b59-cia-3-491]) and CGI-I scores.

In the [@b44-cia-3-491] study, there was a statistically significant improvement at week 10 with aripiprazole 10 mg/d vs placebo group in BPRS total score (aripiprazole −7.12, placebo −4.17; p 0.03) and in the CGI-S (aripiprazole −0.72, placebo, −0.46; p 0.031). There was a significant reduction in the CMAI scores with aripiprazole 5 mg/d and 10 mg/d vs placebo at weeks 6 through 10. There was a significant reduction in the BPRS core score with aripiprazole 5 mg/d vs placebo at weeks 4, 6, and 8, and with 10 mg/d vs placebo at weeks 4 through 10. There was a significant reduction in the NPI-NH total score with aripiprazole 5 mg/d vs placebo at weeks 6 and 8. Aripiprazole 2 mg/day was not efficacious.

[@b34-cia-3-491] analyzed the data from the two studies ([@b54-cia-3-491]; [@b44-cia-3-491]) to investigate further the effect of aripiprazole on agitation as measured by reduction in NPI-Agitation Item, CMAI, and Tension/Hostility/Uncooperativeness/Excitement scores of BPRS. In the [@b54-cia-3-491] study, NPI agitation/aggression, CMAI, and BPRS Tension/Hostility/Uncooperativeness/Excitement scores were significantly reduced at study endpoint (p = 0.001, p \< 0.05, p \< 0.05 respectively). In the [@b44-cia-3-491] study, aripiprazole 5 mg/d and 10 mg/d demonstrated significant reduction (p \< 0.05) of NPI-NH Agitation Item and BPRS Tension/Hostility/Uncooperativeness/Excitement subscore compared with placebo. A significant decrease from baseline on BPRS Tension/Hostility/Uncooperativeness/Excitement subscore was also observed with aripiprazole 2 mg/d (beginning at week 6) at study endpoint (p ≤ 0.05). The effect of aripiprazole on agitation as measured by BPRS Tension/Hostility/Uncooperativeness/Excitement subscore was seen earlier with higher doses (beginning at week 2 with 10 mg/d and beginning at week 4 with 5 mg/d) compared with 2 mg/d.

Discontinuation due to lack of efficacy occurred in 3 patients on aripiprazole and 6 patients on placebo in the [@b16-cia-3-491] study, and in 1 patient on aripiprazole and 3 patients on placebo in the [@b54-cia-3-491]. Discontinuation due to lack of response occurred in 13% of patients on aripiprazole vs 30% of patients on placebo, and time to discontinuation was significantly longer in the aripiprazole group vs the placebo group (p = 0.022) in the [@b54-cia-3-491] study. In the [@b44-cia-3-491] study, discontinuation due to lack of efficacy occurred in 3% of patients on 2 mg/d of aripiprazole, 2% of patients on 5 mg/d of aripiprazole, 2% of patients on 10 mg/d of aripiprazole, and 2% of patients on placebo. Discontinuation due to lack of response occurred in 21% of patients on 2 mg/d of aripiprazole, 16% of patients on 5 mg/d of aripiprazole, 13% of patients on 10 mg/d of aripiprazole, and 24% of patients on placebo. Thus the discontinuation due to lack of response was highest in the lowest-dose group and placebo group.

Tolerability ([Table 2c](#t2c-cia-3-491){ref-type="table"})
-----------------------------------------------------------

In the [@b16-cia-3-491] study, AEs were generally mild to moderate and included (aripiprazole vs placebo): urinary tract infection (8% vs 12%), accidental injury (8% vs 5%), somnolence (8% vs 1%), and bronchitis (6% vs 3%). Somnolence was mild and not associated with falls or accidental injury. There were no significant differences vs placebo in the extrapyramidal symptoms (EPS) scores, or clinically significant electrocardiogram (ECG) abnormalities, vital signs, or weight.

In the [@b54-cia-3-491] study, AEs that occurred at the rate of ≥10% in the aripiprazole group were accidental injury, somnolence, urinary tract infection, ecchymosis, asthenia, vomiting, and rash, and in the placebo group were accidental injury, urinary act infection, ecchymosis, and rash. EPS occurred in 5% of aripiprazole group vs 4% of placebo group, somnolence occurred in 14% of aripiprazole group vs 4% of placebo group, and accidental injuries occurred in 21% of aripiprazole group vs 30% of placebo group.

In the [@b44-cia-3-491] study, AEs occurring at ≥10% incidence in any dosage group of aripiprazole were accidental injury, agitation, peripheral edema, extremity pain, somnolence, urinary incontinence, asthenia, vomiting, and skin ulcer, and in the placebo group, accidental injury, anorexia, ecchymosis, and agitation. EPS occurred in 8% of aripiprazole 2 mg/d group, 7% in aripiprazole 5 mg/d group, 7% in aripiprazole 10 mg/d group, and 6% in the placebo group. Somnolence occurred in 3% of aripiprazole 2 mg/d group, 10% in aripiprazole 5 mg/d group, 7% in aripiprazole 10 mg/d group, and 3% in the placebo group. Accidental injuries occurred in 30% of aripiprazole 2 mg/d group, 24% in aripiprazole 5 mg/d group, 20% in aripiprazole 10 mg/d group, and 19% in the placebo group.

Analysis of the data on mortality in elderly patients with dementia-related psychosis ([@b5-cia-3-491]; pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file) of the three trials ([@b54-cia-3-491]; [@b16-cia-3-491]; Minzter et al 2007) for deaths that occurred during or within 30 days of discontinuation from the placebo-controlled phase of the clinical trial showed that incidence of deaths was 3.5% in aripiprazole-treated patients and 1.7% in placebo-treated patients (p= 0.139). None of the deaths were considered to be treatment-related. Deaths were mostly associated with cardiovascular or infectious conditions.

In these three trials ([@b54-cia-3-491]; [@b16-cia-3-491]; Minzter et al 2007), there was increased incidence of CVAEs (eg, stroke, transient ischemic attack), including fatalities, in aripiprazole-treated patients. In the fixed-dose study of [@b44-cia-3-491] there was a statistically significant dose-response relationship for CVAEs in patients treated with aripiprazole.

In an analysis (pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file) of the three 10-week, placebo-controlled studies of aripiprazole in elderly patients with psychosis associated with AD (n = 938, mean age 82.4 years, range 56--99 years), the treatment-emergent AEs that were reported at an incidence of ≥3% and at least twice that for placebo were lethargy (placebo 2%, aripiprazole 5%), somnolence (including sedation) (placebo 3%, aripiprazole 8%), and incontinence (primarily, urinary incontinence) (placebo 1%, aripiprazole 5%), excessive salivation (placebo 0%, aripiprazole 4%), and lightheadedness (placebo 1%, aripiprazole 4%).

Discontinuation due to AEs occurred in 10 patients on aripiprazole vs 7 patients on placebo in the [@b16-cia-3-491] study, 14% on aripiprazole vs 9% patients on placebo in the [@b54-cia-3-491] study. In the [@b44-cia-3-491] study, discontinuation occurred in 8% on aripiprazole 2 mg/d, 18% on aripiprazole 5 mg/d, 25% on aripiprazole 10 mg/d vs 13% patients on placebo. Thus the discontinuation due to AEs increased with increasing dose. The most common AE leading to discontinuation among the aripiprazole and placebo groups were asthenia and agitation, respectively. Discontinuations due to asthenia appeared to be dose-related, with the greatest number of patients experiencing asthenia in the aripiprazole 10 mg/day dose group (placebo 1%, aripiprazole 2 mg/day 1%, aripiprazole 5 mg/day 2%, and aripiprazole 10 mg/day 4%).

Discussion
==========

The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) study ([@b50-cia-3-491]) evaluated the overall effectiveness of three of the most widely used antipsychotic medications compared with placebo among patients in non-nursing home settings, who were experiencing delusions, hallucinations, aggression, or agitation. The study followed the participants over 9 months and also included the involvement of caregivers. In this 42-site, double-blind, placebo-controlled trial, 421 outpatients suffering from AD and having psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg/d), quetiapine (mean dose, 56.5 mg/d), risperidone (mean dose, 1.0 mg/d), or placebo. There were no significant differences among treatments for the main outcome measures, ie, time to discontinuation of treatment for any reason and number of patients with at least minimal improvement on the Clinical Global Impression of Change (CGIC) ([@b51-cia-3-491]) scale at 12 weeks. The median time to discontinuation of treatment due to a lack of efficacy favored olanzapine and risperidone over quetiapine and placebo. The time to discontinuation of treatment due to adverse events or intolerability favored placebo. This study showed that the adverse effects of atypical antipsychotics offset their benefits in the treatment of psychosis, aggression, or agitation in patients with AD.

The flexible dose studies of aripiprazole showed modest effect ([@b54-cia-3-491]; [@b16-cia-3-491]). In these two studies, which assessed the efficacy of flexible doses of aripiprazole up to 15 mg/d in patients with AD, the change from baseline NPI-NH Psychosis Subscale score was similar for the aripiprazole and placebo groups, with significant improvements compared with placebo in secondary measures of psychosis (eg, BPRS score subscale and psychosis subscale) ([@b16-cia-3-491]) and other behavioral symptoms (eg, CMAI, CDDS, CGI-I, NPI-NH scores) ([@b54-cia-3-491]) in patients suffering from psychosis associated with AD. The study assessing the efficacy of fixed doses of aripiprazole ([@b44-cia-3-491]) showed that aripiprazole 10 mg/d was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms and agitation, and showed improvement in both primary and secondary outcome measures in that patient population.

The safety and tolerability profile of antipsychotic treatment is of particular concern in elderly patients who are more susceptible to adverse effects such as EPS, delirium due to anticholinergic adverse events, and orthostatic hypotension. There is also a high prevalence of co-existing metabolic (eg, high cholesterol, diabetes mellitus) and cardiovascular illnesses (eg, hypertension, ischemic heart disease) in the elderly. In addition, AEs may be associated with falls and accidents resulting in fractures in the elderly. Hence the risk of such AEs should be considered while choosing a medication and making treatment decisions. It is therefore important to note that the incidence of EPS-related AEs in these studies was low across all treatment groups. This concurs with the safety profile of aripiprazole in patients with schizophrenia and bipolar disorder in adults and in elderly patients ([@b40-cia-3-491]; [@b38-cia-3-491]; [@b49-cia-3-491]). However, not all studies with atypical antipsychotics in patients with AD have shown EPS-related adverse events similar to placebo ([@b53-cia-3-491]). High levels of somnolence may also be associated with falls in the elderly. In the two studies assessing the flexible doses of aripiprazole, occurrence of somnolence showed a \>5% difference between the aripiprazole and placebo groups. In the study assessing fixed doses of aripiprazole, the incidence of somnolence with aripiprazole was low (7% at the 10 mg/d dose) and did not increase with dose. Higher somnolence rates have been observed in previous studies with other atypical antipsychotics. for example, 36.5% with risperidone ([@b6-cia-3-491]) and 35.8% with olanzapine ([@b53-cia-3-491]). There was no significant difference between placebo and aripiprazole in all the three studies for weight change, in contrast to studies with other atypical antipsychotics where significantly higher weight gain was observed with both olanzapine ([@b14-cia-3-491]) and risperidone ([@b6-cia-3-491]) vs placebo in patients with AD.

Recently, CVAEs have emerged as a significant issue with the use of atypical antipsychotics in elderly individuals ([@b61-cia-3-491], [@b62-cia-3-491]). This led the FDA to issue a warning. However, some retrospective cohort studies have suggested that conventional and atypical antipsychotics do not differ significantly in their risk of CVAEs ([@b27-cia-3-491]; [@b23-cia-3-491]) or mortality ([@b58-cia-3-491]) in older adults. CVAEs were reported for 7 aripiprazole-treated patients during the [@b44-cia-3-491] fixed dose study (1 in the 2 mg/d dose group, 2 in the 5 mg/d dose group, and 4 in the 10 mg/d dose group), compared with no patients in the placebo group. The effect was statistically dose-dependent (p = 0.03, Cochran--Mantel--Haenszel \[CMH\] row means score test). All CVAEs reported with aripiprazole occurred in subjects with a prior history of CVA, stroke, or related risk factors. It is also important to note that the FDA has issued a black box warning for increased mortality risk in elderly patients with dementia, treated with atypical antipsychotics ([@b56-cia-3-491]). Analyses of 17 placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of 1.6 to 1.7 times to that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared with a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be the result of either cardiovascular causes (eg, heart failure, sudden death) or infections (eg, pneumonia). Aripiprazole should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions that would predispose patients to hypotension. The risks and benefits of arpipirazole in the treatment of psychosis of AD should be considered by the clinicians and discussed with the patients/caregivers ([@b52-cia-3-491]).

A thorough evaluation of the medical and psychiatric status along with a comprehensive treatment approach including environmental manipulation are required prior to considering use of atypical antipsychotic in patients with psychosis associated with AD. The efficacy results in the study by [@b44-cia-3-491] show that aripiprazole 10 mg/d is an effective dose for these patients, although some patients achieved significant benefit with aripiprazole 5 mg/d. The dose--effectiveness relationship is further supported by the rate of discontinuation due to lack of efficacy, which was greatest in the 2 mg/d dose group. However, when selecting an appropriate dose, the discontinuation rate due to dose-related adverse events should also be considered. The rates of discontinuation due to adverse events for the 5 and 10 mg/d doses (18% and 25%, respectively) were higher than those reported in the flexible-dose aripiprazole studies in noninstitutionalized patients (9.4%) ([@b16-cia-3-491]) and in institutionalized patients (14%) ([@b54-cia-3-491]). In both of the flexible-dose studies, patients were started with 2 mg/d and titrated gradually to higher aripiprazole doses. This suggests that slow titration from a low initial dose may improve the tolerability and prove to be the most clinically appropriate strategy for starting aripiprazole treatment in this elderly patient population.

Conclusion
==========

The control of psychotic symptoms is important for improving outcome in elderly patients with AD. Furthermore, treatment of the psychotic symptoms improves patient quality of life, decreases caregiver burden, decreases the need for institutionalization, and reduces overall healthcare costs. There are no psychotropic medications approved by the FDA for the treatment of psychosis of AD. The limited evidence available for atypical antipsychotics suggests that they offer modest benefits over placebo for treating psychosis. The studies evaluating aripiprazole suggest that it may also be beneficial in treatment of psychosis for patients with AD. However, the benefits of relieving psychosis need to be balanced against the risk of neurologic, metabolic, and cardiovascular AEs in each individual patient. The safety and tolerability profile seen with aripiprazole suggests a low potential for negative impact on overall patient health and makes aripiprazole a reasonable treatment option. However, in the absence of head-to-head comparison studies between aripiprazole and other atypical antipsychotics, it is difficult to conclude whether there is any added value of the uses of aripiprazole. Further studies comparing the efficacy and tolerability of aripiprazole versus other atypical antipsychotics in psychosis of AD are needed to guide treatment choice among the atypical antipsychotics agents.
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###### 

Diagnostic Criteria for psychosis of Alzheimer's disease (PAD) (after [@b30-cia-3-491])

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristic symptoms**
  Presence of ≥1 of the following:
  Visual or auditory hallucinations
  Delusions
  **Primary diagnosis**
  All criteria for dementia of Alzheimer's type are met.
  **Chronology of onset of psychosis symptoms versus onset of dementia symptoms**
  There is evidence from the history that the characteristic symptoms have not been present continuously before the onset of dementia symptoms.
  **Duration and severity**
  Characteristic symptoms have been present, at least intermittently, for ≥1 month. Symptoms are severe enough to cause some disruption in the patient's and/or other's functioning.
  **Exclusion of schizophrenia and related psychotic disorders**
  Criteria for schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features have never been met.
  **Relationship to delirium**
  The disturbance does not occur exclusively during course of a delirium.
  **Exclusion of other causes of psychotic symptoms**
  The disturbance is not better accounted for by another general medical condition or direct physiological effects of a substance (eg, a drug of abuse or medication).
  **Associated features (specify)**
  With agitation-when there is evidence from history or examination of prominent agitation with or without physical or verbal aggression.
  With negative symptoms -- when prominent negative symptoms, such as apathy, affective flattening, avolition, or motor retardation, are present.
  With depression -- when prominent depressive symptoms, such as depressed mood, insomnia or hypersomnia, feelings of worthlessness or excessive or inappropriate guilt, or recurrent thoughts of death, are present.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Methodology -- placebo-controlled studies of aripiprazole in patients with AD-related psychosis (pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference             Patient population                                           Study design                                                                             Study medication
  --------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  De Dedyn et al 2005   208 outpatients\                                             10 week, randomized double-blind, multi-center placebo-controlled, flexible dose study   Aripiprazole 2--15 mg/d (n = 106)\
                        Mean age (in years) 81.5, range 55--95\                                                                                                               Titrated Q 2 weeks as needed\
                        Mean MMSE score = 14.35 (aripiprazole).\                                                                                                              Mean end point dose = 10 mg/d\
                        14.13 (placebo) delusions/hallucinations ≥ 1 month\                                                                                                   Placebo (n = 102)
                        NPI delusions/hallucinations score ≥6                                                                                                                 

  [@b54-cia-3-491]      256 inpatients\                                              10 week, randomized double-blind, multi-center placebo-controlled, flexible dose study   Aripiprazole 2--15 mg/d (n = 131)\
                        Mean age (in years) 83; range 59--96\                                                                                                                 Week 1 to weeks 6--10 from 2 mg/d to 15 mg/d\
                        Mean MMSE score = 12.9 delusions/hallucinations ≥ 1 month\                                                                                            Mean end point dose = 8.6 mg/d\
                        NPI delusions/hallucinations score ≥6                                                                                                                 Placebo (n = 125)

  [@b44-cia-3-491]      487 inpatients\                                              10 week, randomized double-blind, multi-center placebo-controlled, fixed dose study      Aripiprazole 2 mg/d (n = 118)\
                        Mean age, years 82.2, (range) 56.0--96.0\                                                                                                             Aripiprazole 5 mg/d (n = 122)\
                        Mean MMSE score = 12.4 delusions/hallucinations\                                                                                                      Aripiprazole 5 mg/d × 7d, then 10 mg/d (n = 126)\
                        ≥ 1 month\                                                                                                                                            Placebo (n = 121) by week 6, patient with CGI-I ≥4 were allowed open-label treatment with aripiprazole through week 10
                        NPI delusions/hallucinations score ≥6                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CGI-I, Clinical Global Impression of Improvement; MMSE, Mini Mental State Exam; NPI, Neuropsychiatric Inventory.

###### 

Results -- efficacy (pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file)

  Reference          Primary outcome                                                                                                       Secondary outcome                                                                       Discontinuations                                                                                                                                                                                                                                                                                                                                      
  ------------------ --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------ --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------- ----------------- ----------------------------------------------------------------- ---------- ------------------- ---------
  [@b16-cia-3-491]   Caregiver NPI psychosis subscale Score at week 10                                                                     Mean change in BPRS total score (week 10)                                               Lack of efficacy                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                           Psychosis Score                                                                         p-value                                                                                                                                                                                                   Aripiprazole   Placebo   p-value           Aripiprazole                                                                 Placebo             
                     Aripoprazole                                                                                                          −6.55                                                                                   NS                                                                                                                                                                                                        −8.53          −6.58     NS                3 patients                                                                   6 patients          
                     Placebo                                                                                                               −5.52                                                                                   NS                           Significant improvement on BPRS psychosis and core subscale for aripiprazole vs placebo at weeks 8 and 10 (p \< 0.05)                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                             Aripiprazole   Placebo   p-value                                                                                                            
                                                                                                                                                                                                                                                                NPI total                                                                                                                                                                    −9.75          −11.20    NS                                                                                                                 
                                                                                                                                                                                                                                                                CGI-S                                                                                                                                                                        −0.69          −0.54     NS                                                                                                                 
                                                                                                                                                                                                                                                                MMSE                                                                                                                                                                         −0.81          −0.53     0.001                                                                                                              
                                                                                                                                                                                                                                                                CGI-I                                                                                                                                                                        3.17           3.07      NS                                                                                                                 
  [@b54-cia-3-491]   NPI Psychosis Subscale score at week 10                                                                               Changes in NPI-NH total scores at week 10                                               Lack of efficacy             Placebo                                                                                                                                                                                                                                                                                                                  
                     • NS between aripiprazole and placeboMean change in CGI-S                                                                                                                                                     Aripiprazole       Placebo   p-value                                                                                                                                                                      Aripiprazole             3 patients (2%)                                                                                                    
                                                                                                                                                                                                                                                                Total score                                                                                                                                                                  −16.4          −10.0     0.009             1 patient (1%)                                                                                   
                     • Decrease in both groups, but significant in aripiprazole vs placebo only at week 8 (p \< 0.05)                      Response to treatment (≥50% reduction in NPI total score)                               Lack of response                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                             Aripiprazole   Placebo   p-value           Aripiprazole                                                                 Placebo             
                                                                                                                                                                                                                                                                \% of patients                                                                                                                                                               46%            28%       0.006             17 patients (13%)                                                            38 patients (30%)   
                                                                                                                                                                                                                                                                Endpoint                                                                                                                                                                                                                Time to discontinue significantly longer vs placebo (p = 0.022)                                  
                                                                                                                                                                                                                                                                BPRS total score                                                                                                                                                             −7.7           −5.1      0.031                                                                                                              
                                                                                                                                                                                                                                                                CDDS total score                                                                                                                                                             −0.13          −1.98     0.006                                                                                                              
                                                                                                                                                                                                                                                                Significantly greater improvement in aripiprazole vs placebo on CMAI (p \< 0.05) CGI-I significantly greater in aripiprazole vs placebo (p \< 0.05 weeks 2, 3,6,8, and 10)                                                                                                                                               
  [@b44-cia-3-491]   Mean change on NPI-NH psychosis subscale                                                                              Week 10 results                                                                                                                                                                                                                                                                                   Aripiprazole                               Placebo                                                                                          
                                                                                                                                           Aripiprazole (10 mg/day)                                                                Placebo            p-value                                                                                                                                                                                Aripiprazole   Placebo   p-value           2 mg/d                                                            5 mg/d     10 mg/d             
                                                                                                                                                                                                                                                                BPRS total                                                                                                                                                                   −7.12          −4.17     0.030             Lack of efficacy                                                                                 
                     Endpoint score                                                                                                        −6.87                                                                                   −5.13              0.013     CGI-S                                                                                                                                                                        −0.72          −0.46     0.031             3(3%)                                                             2(2%)      3(2%)               2(2%)
                     Response to treatment ≥50% reduction in NPI-NH psychosis subscale                                                     NPI-NH-total-significant reduction vs placebo for aripiprazole 5 mg/d at week 6 and 8   Lack of response                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        25 (21%)                                                          19 (16%)   17 (13%)            29(24%)
                     Week 10                                                                                                               65%                                                                                     50%                0.019     BPRS total significant reduction vs placebo for aripiprazole 5 mg/d at week 4, 6, and 8 and for 10 mg/d at weeks 4 through 10                                                                                                                                                                                            
                     Mean change in NPI-NH psychosis subscale was also significantfor aripiprazole 5 mg vs placebo at week 8 (p \< 0.05)   CMAI-significant reduction vs placebo for aripiprazole 5 and 10 mg/d at weeks 6--10                                                                                                                                                                                                                                                                                                                                                           

**Abbreviations:** BPRS, Brief Psychiatric Rating Scale; CMAI, Cohen-Mansfield Agitation Inventory; CDDS, Cornell Depression in Dementia Scale; CGI-I, Clinical Global Impression of Improvement; CGI-S, Clinical Global Impression-Severity of Illness; MMSE, Mini Mental State Exam; NPI, Neuropsychiatric Inventory; NPI-NH, Neuropsychiatric Inventory-Nursing Home.

###### 

Results -- safety (pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference          Discontinuation due to adverse events   Most commonly reported adverse events   EPS           Somnolence                                                                                                       Accidental injuries                                                                                                                                         Other                                                                                                                                                                                                  
  ------------------ --------------------------------------- --------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------- ------------ ------------------------------------------- ------------- --------------------------------- ------------------------- ----------------- ------------- ---------------------------------
  [@b16-cia-3-491]   Aripiprazole 21%                                                                Placebo 15%   Aripiprazole \> placebo accidental injury (ie. falls) (8.5% vs 5%) somnolence (8% vs 1%) bronchitis (6% vs 3%)   Aripiprazole 10%                                                                                                                                            Placebo 8%        Aripiprazole 8%   Placebo 1%   Aripiprazole 17%                            Placebo 10%   \> 7% weight gain from baseline                                                             

                                                                                                                                                                                                                                    Placebo \> aripiprazole urinary tract infection (12% vs 8%) hypertension (5% vs 4%)                                                                                                                                                                                                                      7 resulted in fractures   Aripiprazole 5%                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             3 treatment related       Placebo 3% NS                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Lab tests and Vital signs-NS

  [@b54-cia-3-491]   Aripiprazole 14%                                                                              Placebo 9%                                                                                                       Aripiprazole \> 10%                                                                                                                                         Aripiprazole 5%                     Placebo 4%   Aripiprazole 14%                                          Placebo 4%                        Aripiprazole 21%                            Placebo 30%   Orthostatic hypotension/syncope

                                                                                                                                                                                                                                    Accidental injury somnolence, urinary tract infection echymosis, asthenia, vomiting, rash                                                                                                                    2 patients discontinued due to somnolence                                                                                                             Aripiprazole 3%

                                                                                                                                                                                                                                    Placebo \> 10% accidental injury, urinary tract infection, echymosis, rash                                                                                                                                                                                                                                                                                         Placebo 5%

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ECG changes: NS

  [@b44-cia-3-491]   Aripiprazole                                                                    Placebo 13%   Aripiprazole \> 10% in any dosage group                                                                          Aripiprazole                                                                                                                                                                  Aripiprazole                   Aripiprazole                                                                                                                                          

                     2 mg/d\                                 5 mg/d\                                 10 mg/d\                                                                                                                       Accidental injury, urinary tract infection, agitation, peripheral edema, extremity pain, asthenia, vomiting, somnolence, skin ulcer, urinary incontinence   2 mg/d\           5 mg/d\           10mg/d\      2 mg/d\                                     5 mg/d\       10 mg/d\                          2 mg/d\                   5 mg/d\           10 mg/d\      
                     8%                                      18%                                     25%                                                                                                                                                                                                                                                                                        8%                7%                7%           3%                                          10%           7%                                30%                       24%               20%           

                                                                                                                                                                                                                                    Placebo \> 10%                                                                                                                                              Placebo 6%                          Placebo 3%                                               Placebo 19%                                                                                               

                                                                                                                                                                                                                                    Accidental injury, anorexia, echymosis, agitation                                                                                                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** EPS, extrapyramidal symptoms; NS = not significant.
